Cite
HARVARD Citation
Foley, J. et al. (2023). Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. Multiple sclerosis. pp. 196-205. [Online].